+48.9%
ASTS vs MRNA
+511.3%
-462.4%
-60.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.3% | -2.2% | +2.5% | +0.4% |
| 7D | +7.3% | +5.5% | +1.9% | +6.9% |
| 30D | -8.9% | +158.7% | -167.6% | -22.6% |
| 3M | -41.9% | +182.1% | -224.1% | -52.9% |
| 6M | -40.6% | +151.8% | -192.4% | -49.6% |
| YTD | -14.2% | +393.6% | -407.8% | -48.1% |
| 1Y | +48.9% | +499.5% | -450.6% | -18.4% |
| All | +48.9% | +511.3% | -462.4% | -18.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling